Actively Recruiting

Age: 50Years +
All Genders
Healthy Volunteers
NCT06034405

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Led by Columbia University · Updated on 2025-11-12

1663

Participants Needed

6

Research Sites

240 weeks

Total Duration

On this page

Sponsors

C

Columbia University

Lead Sponsor

N

National Institute on Aging (NIA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Primary objective: To identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are most effective. The specific aims of this epidemiologic investigation include: 1. To identify subjects with previous lumbar spinal stenosis (LSS) Surgery who have evidence of transthyretin (TTR) amyloid deposits in spinal specimens and could be at risk for ATTR cardiac amyloidosis. 2. To evaluate for ATTR-CA among those with localized TTR in the spinal tissue. The study will also explore the following: 1. The prevalence of amyloid in lumbar spinal stenosis specimens by Congo Red staining. 2. The prevalence of TTR deposits among subjects with amyloid as determined by mass spectrometry. 3. Evaluation of a novel artificial intelligence technique for that can identify amyloid histologically with standard H\&E staining. 4. Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in subject's spine by myocardial uptake of technetium pyrophosphate scan (Tc99-PYP).

CONDITIONS

Official Title

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Who Can Participate

Age: 50Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinically indicated spinal decompressive surgery within 20 years prior to enrollment
  • Age 50 years or older at the time of the surgery
  • Able to understand and sign the informed consent document after the nature of the study has been fully explained
Not Eligible

You will not qualify if you...

  • Confirmed primary amyloidosis (AL) or secondary amyloidosis (AA)
  • Known transthyretin amyloidosis
  • Any other reason that would make the subject inappropriate for entry into this study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Cedars-Sinai Medical Center

Beverly Hills, California, United States, 90211

Actively Recruiting

2

Tufts Medical Center

Boston, Massachusetts, United States, 02111

Actively Recruiting

3

Boston Medical Center

Boston, Massachusetts, United States, 02359

Actively Recruiting

4

Mayo Clinic

Rochester, Minnesota, United States, 55905

Active, Not Recruiting

5

Columbia University Irving Medical Center

New York, New York, United States, 10032

Actively Recruiting

6

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

Loading map...

Research Team

M

Mathew S Maurer, MD

CONTACT

S

Samantha L Guadalupe, MHA

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here